Table 2.
Multivariable Logistic Regression on Factors Associated With PCSK9 Inhibitor Initiation
| Patient Characteristic | PCSK9 Inhibitor Initiation | |
|---|---|---|
| OR (95% CI) | P Value | |
| Age, y | 1.00 (0.99–1.02) | 0.58 |
| Women | 1.44 (1.22–1.68) | <0.001 |
| Race/ethnicity | ||
| White | 1 (Reference) | |
| Black | 0.79 (0.61–1.03) | 0.08 |
| Hispanic | 1.03 (0.80–1.31) | 0.83 |
| Asian | 0.64 (0.39–1.07) | 0.09 |
| Unknown | 0.76 (0.58–1.01) | 0.06 |
| US region | ||
| Northeast | 1 (Reference) | |
| South | 0.92 (0.72–1.17) | 0.50 |
| Midwest | 0.73 (0.53–0.99) | 0.04 |
| West | 1.09 (0.83–1.44) | 0.53 |
| Unknown | 2.12 (0.58–7.71) | 0.25 |
| Annual household income, $ | ||
| <50 000 | 1 (Reference) | |
| 50 000–99 999 | 1.31 (1.05–1.65) | 0.02 |
| >$100 000 | 2.06 (1.66–2.55) | <0.001 |
| Unknown | 1.00 (0.78–1.28) | 0.98 |
| Hypertension | 0.85 (0.69–1.04) | 0.11 |
| Diabetes mellitus | 0.85 (0.73–1.00) | 0.05 |
| MACE in past year | 0.60 (0.50–0.72) | <0.001 |
| Baseline LDL‐C, mg/dL | ||
| 70–99 | 1 (Reference) | |
| 100–129 | 5.79 (4.75–7.06) | <0.001 |
| ≥ 130 | 36.29 (30.09–43.77) | <0.001 |
| Cardiology outpatient visit in past year | 2.80 (2.27–3.45) | <0.001 |
LDL‐C indicates low‐density lipoprotein cholesterol; MACE, major adverse cardiovascular event; OR, odds ratio; and PCSK9, proprotein convertase subtilisin/kexin type 9.
Patients included in the model were patients with ASCVD with high adherence to a high‐intensity statin and LDL‐C ≥70 mg/dL who were not started on a PCSK9 inhibitor as well as patients with ASCVD with LDL‐C ≥70 mg/dL who were initiated on a PCSK9 inhibitor.